Beckman Coulter Diagnostics will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyser, at Medlab Middle East in Dubai, taking place 5-8 February. The new analyser expands the company’s portfolio with proven Six Sigma performance and aims to complement hub laboratories by advancing the capabilities of satellite and independent community hospital sites.
“Healthcare systems around the world are strategically adopting hub-and-spoke models for better efficiency and healthcare access,” said Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics. “Hub-and-spoke clinical laboratory models optimise resources to improve access to testing services and enhance overall standardisation for quality testing and positive impact on inventory and cost management across a health system. The new DxC 500 AU Chemistry Analyzer advances capabilities of spoked labs with a broad menu of high-quality assays that deliver consistent, commutable results across Beckman Coulter's AU clinical chemistry systems positively impacting clinical decision-making and patient outcomes.”
The DxC 500 AU Chemistry Analyzer features advanced automation technology, onboard guided workflows, and standardised reagents for use across healthcare networks. Its menu of more than 120 assays has been independently and objectively verified for high quality Six Sigma performance, supporting confidence in clinical results, reducing QC trouble shooting and operational costs.
"Our Six Sigma assessment has shown that the DxC 500 AU analyser easily exceeds the demands of the new, more stringent CLIA 2024 performance specifications," stated Sten Westgard, Director of Client Services and Technology for Westgard QC.
The DxC 500 AU Chemistry Analyzer is for in vitro diagnostic use only. Global commercial availability is planned for March 2024.